Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris M Parry

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The Journal of Antimicrobial Chemotherapy|May 29, 2013
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort studyDavid I Dolling, David T Dunn, Katherine A Sutherland, et al.
The Journal of Antimicrobial Chemotherapy|August 1, 2024
Whole-body distribution of tenofovir, emtricitabine and dolutegravir in non-human primatesThibaut Gelé, Hélène Gouget, Nastasia Dimant, et al.
Retrovirology|May 17, 2011
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domainsJean L Mbisa, Ravi K Gupta, Desire Kabamba, et al.
Plos One|September 19, 2015
Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA TrialKatherine A Sutherland, Chris M Parry, Adele McCormick, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2014
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitorsAdriaan E Basson, Soo-Yon Rhee, Chris M Parry, et al.
Plos One|June 3, 2016
Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA TrialKatherine A Sutherland, Chris M Parry, Adele McCormick, et al.
Viruses|June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
AIDS (London, England)|September 30, 2014
Rates of HIV-1 superinfection and primary HIV-1 infection are similar in female sex workers in UgandaAndrew D Redd, Deogratius Ssemwanga, Judith Vandepitte, et al.
Plos One|December 25, 2015
Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in UgandaPontiano Kaleebu, Wilford Kirungi, Christine Watera, et al.
The Journal of Infection|May 11, 2018
Activation of coagulation and endothelium with concurrent impairment of anticoagulant mechanisms in patients with typhoid feverHanna K de Jong, Chris M Parry, Thomas W van der Vaart, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Journal of Antimicrobial Chemotherapy|May 29, 2013
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort studyDavid I Dolling, David T Dunn, Katherine A Sutherland, et al.
The Journal of Antimicrobial Chemotherapy|August 1, 2024
Whole-body distribution of tenofovir, emtricitabine and dolutegravir in non-human primatesThibaut Gelé, Hélène Gouget, Nastasia Dimant, et al.
Retrovirology|May 17, 2011
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domainsJean L Mbisa, Ravi K Gupta, Desire Kabamba, et al.
Plos One|September 19, 2015
Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA TrialKatherine A Sutherland, Chris M Parry, Adele McCormick, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2014
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitorsAdriaan E Basson, Soo-Yon Rhee, Chris M Parry, et al.
Plos One|June 3, 2016
Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA TrialKatherine A Sutherland, Chris M Parry, Adele McCormick, et al.
Viruses|June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
AIDS (London, England)|September 30, 2014
Rates of HIV-1 superinfection and primary HIV-1 infection are similar in female sex workers in UgandaAndrew D Redd, Deogratius Ssemwanga, Judith Vandepitte, et al.
Plos One|December 25, 2015
Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in UgandaPontiano Kaleebu, Wilford Kirungi, Christine Watera, et al.
The Journal of Infection|May 11, 2018
Activation of coagulation and endothelium with concurrent impairment of anticoagulant mechanisms in patients with typhoid feverHanna K de Jong, Chris M Parry, Thomas W van der Vaart, et al.
Pageof 4